Isabel Nájera

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

Edward Gane, Stuart K. Roberts, Catherine AM Stedman et al. · The Lancet · 2010 · 336 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy

Isabel Nájera, África Holguín, Miguel E. Quiñones‐Mateu et al. · Journal of Virology · 1995 · 236 citations · Full text

Life Sciences, Infectious Diseases, Molecular Genetics +17

The Novel Nucleoside Analog R1479 (4′-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture

Klaus Klumpp, Vincent Lévêque, Sophie Le Pogam et al. · Journal of Biological Chemistry · 2005 · 215 citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +15

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

Matthew F. McCown, Sonal Rajyaguru, Sophie Le Pogam et al. · Antimicrobial Agents and Chemotherapy · 2008 · 164 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +17

Resistance Profile of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Abacavir (1592U89) after Monotherapy and Combination Therapy

P. Richard Harrigan, Christopher Stone, Phillip Griffin et al. · The Journal of Infectious Diseases · 2000 · 158 citations

Life Sciences, Pharmacology, Pharmacotherapy +17